-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Pasithea Therapeutics Appoints Life Sciences and Health Care Executive Alfred J. Novak to Its Board of Directors
Pasithea Therapeutics Appoints Life Sciences and Health Care Executive Alfred J. Novak to Its Board of Directors
Mr. Novak brings over 30 years of board and management experience at innovative life sciences companies
MIAMI BEACH, Fla., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) ("Pasithea" or the "Company"), a biotechnology company focused on the discovery, research and development of new and effective treatments for central nervous system ("CNS") disorders, today announced that Alfred J. Novak was appointed to its Board of Directors (the "Board"). Mr. Novak replaces Dr. Yassine Bendiabdallah, who stepped down from the Board on September 14, 2022.
Mr. Novak has broad operating experience as a Chief Executive Officer and Chief Financial Officer and has served on the boards of several pharmaceutical and medical device companies. Mr. Novak brings financial acumen and extensive expertise in product development, regulatory approval, commercial activities, and a track record of delivering substantial value for stockholders. Mr. Novak served as a director of Dova Pharmaceuticals, which was sold to Swedish Orphan Biovitrum AB or Sobi™, a company focused on rare diseases, for over $900 million; a director and CEO of Biosense, which was sold to Johnson & Johnson for $400 million; and CFO of Cordis Corporation, which was acquired by Johnson & Johnson for $1.8 billion. He received his MBA from the Wharton School of the University of Pennsylvania with a concentration in Healthcare Administration and a BS from the United States Merchant Marine Academy.
Professor Lawrence Steinman, Chairman of the Board of Pasithea, stated, "We are pleased to welcome Mr. Novak to our Board of Directors. We are thrilled that an individual of Al's caliber has joined Pasithea's Board and his input will be invaluable as we continue our progress toward developing proprietary drug candidates and achieve value-creating milestones. The Board would like to express its appreciation to Dr. Bendiabdallah for all his dedication and contributions to Pasithea."
Mr. Novak commented, "Pasithea is an exciting company with a promising portfolio of assets, encouraging pre-clinical results for its lead drug candidates and a world recognized team of scientists. I am honored to join Pasithea's Board and will work with my fellow directors and the management team to develop novel and groundbreaking therapies to improve patients' lives and create shareholder value."
About Pasithea Therapeutics Corp.
Pasithea Therapeutics Corporation is a biotechnology company focused on the discovery, research and development of new and effective treatments for central nervous system (CNS) disorders. With an experienced team of experts in the fields of neuroscience and psychopharmacology, Pasithea is developing new molecular entities for the treatment of psychiatric and neurological disorders, including Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS). Pasithea addresses the needs of patients currently suffering with mental illness by providing access to IV ketamine infusions both in clinics and in-home settings.
Forward Looking Statements
This press release contains statements that constitute "forward-looking statements." Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company's filings with the SEC. Thus, actual results could be materially different. The Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, after the date of this release, except as required by law. Such forward-looking statements are subject to risks (including those set forth in the Company's Form 10-K for the fiscal year ended December 31, 2021, as amended, filed with the U.S. Securities and Exchange Commission) and uncertainties which could cause actual results to differ from the forward-looking statements.
Pasithea Therapeutics Corp. Company Contact
Dr. Tiago Reis Marques
Chief Executive Officer
E: tiago@pasithea.com
Pasithea Therapeutics Corp. Investor Relations
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
Pasithea Therapeutics Corp. Media Contact
Caitlin Kasunich
KCSA
E: ckasunich@kcsa.com
Mr. Novak brings over 30 years of board and management experience at innovative life sciences companies
诺瓦克先生在创新的生命科学公司拥有30多年的董事会和管理经验
MIAMI BEACH, Fla., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) ("Pasithea" or the "Company"), a biotechnology company focused on the discovery, research and development of new and effective treatments for central nervous system ("CNS") disorders, today announced that Alfred J. Novak was appointed to its Board of Directors (the "Board"). Mr. Novak replaces Dr. Yassine Bendiabdallah, who stepped down from the Board on September 14, 2022.
佛罗里达州迈阿密海滩,9月环球通讯社2022年20日电专注于发现、研究和开发治疗中枢神经系统疾病的新型有效疗法的生物技术公司帕西西亚治疗公司(纳斯达克代码:KTTA)(“帕西西亚”或“公司”)今天宣布,任命阿尔弗雷德·J·诺瓦克为其董事会成员(“董事会”)。诺瓦克将接替亚辛·本迪亚布达拉博士,后者于2022年9月14日从董事会辞职。
Mr. Novak has broad operating experience as a Chief Executive Officer and Chief Financial Officer and has served on the boards of several pharmaceutical and medical device companies. Mr. Novak brings financial acumen and extensive expertise in product development, regulatory approval, commercial activities, and a track record of delivering substantial value for stockholders. Mr. Novak served as a director of Dova Pharmaceuticals, which was sold to Swedish Orphan Biovitrum AB or Sobi™, a company focused on rare diseases, for over $900 million; a director and CEO of Biosense, which was sold to Johnson & Johnson for $400 million; and CFO of Cordis Corporation, which was acquired by Johnson & Johnson for $1.8 billion. He received his MBA from the Wharton School of the University of Pennsylvania with a concentration in Healthcare Administration and a BS from the United States Merchant Marine Academy.
诺瓦克先生作为首席执行官和首席财务官拥有广泛的运营经验,并曾在几家制药和医疗设备公司的董事会任职。诺瓦克先生在产品开发、监管审批、商业活动方面拥有敏锐的金融洞察力和广泛的专业知识,并拥有为股东带来可观价值的记录。诺瓦克曾担任多瓦制药公司董事的一员,后者以逾9亿美元的价格被瑞典孤儿Biovitrum AB或SOBI™收购;担任董事的董事兼Biosense的首席执行长,后者以4亿美元的价格被强生收购;以及科迪斯公司的首席财务官,后者被强生以18亿美元的价格收购。他在宾夕法尼亚大学沃顿商学院获得MBA学位,主修医疗管理,并在美国商船学院获得学士学位。
Professor Lawrence Steinman, Chairman of the Board of Pasithea, stated, "We are pleased to welcome Mr. Novak to our Board of Directors. We are thrilled that an individual of Al's caliber has joined Pasithea's Board and his input will be invaluable as we continue our progress toward developing proprietary drug candidates and achieve value-creating milestones. The Board would like to express its appreciation to Dr. Bendiabdallah for all his dedication and contributions to Pasithea."
Pasithea公司董事会主席劳伦斯·斯坦曼教授说:“我们很高兴欢迎诺瓦克先生加入我们的董事会。我们对Al这样有才华的人加入Pasithea公司董事会感到兴奋,他的贡献将是无价的,因为我们将继续在开发专利候选药物和实现创造价值的里程碑方面取得进展。董事会要对Bendiabdallah博士对Pasithea公司的所有奉献和贡献表示感谢。”
Mr. Novak commented, "Pasithea is an exciting company with a promising portfolio of assets, encouraging pre-clinical results for its lead drug candidates and a world recognized team of scientists. I am honored to join Pasithea's Board and will work with my fellow directors and the management team to develop novel and groundbreaking therapies to improve patients' lives and create shareholder value."
诺瓦克先生评论说:“Pasithea是一家令人兴奋的公司,拥有前景看好的资产组合,它的主要候选药物和世界公认的科学家团队的临床前结果令人鼓舞。我很荣幸加入Pasithea董事会,并将与我的董事同事和管理团队合作,开发新颖和突破性的疗法,以改善患者的生活并创造股东价值。”
About Pasithea Therapeutics Corp.
Pasithea治疗公司简介
Pasithea Therapeutics Corporation is a biotechnology company focused on the discovery, research and development of new and effective treatments for central nervous system (CNS) disorders. With an experienced team of experts in the fields of neuroscience and psychopharmacology, Pasithea is developing new molecular entities for the treatment of psychiatric and neurological disorders, including Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS). Pasithea addresses the needs of patients currently suffering with mental illness by providing access to IV ketamine infusions both in clinics and in-home settings.
Pasithea治疗公司是一家生物技术公司,专注于发现、研究和开发治疗中枢神经系统(CNS)疾病的新的有效疗法。Pasithea在神经科学和精神药理学领域拥有一支经验丰富的专家团队,正在开发用于治疗精神和神经疾病的新分子实体,包括肌萎缩侧索硬化症(ALS)和多发性硬化症(MS)。Pasithea通过在诊所和家庭环境中提供静脉注射氯胺酮来满足目前患有精神疾病的患者的需求。
Forward Looking Statements
前瞻性陈述
This press release contains statements that constitute "forward-looking statements." Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company's filings with the SEC. Thus, actual results could be materially different. The Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, after the date of this release, except as required by law. Such forward-looking statements are subject to risks (including those set forth in the Company's Form 10-K for the fiscal year ended December 31, 2021, as amended, filed with the U.S. Securities and Exchange Commission) and uncertainties which could cause actual results to differ from the forward-looking statements.
本新闻稿包含构成“前瞻性陈述”的陈述。前瞻性陈述受许多条件的制约,其中许多条件不在公司的控制范围之内。虽然公司相信这些前瞻性陈述是合理的,但不应过度依赖任何此类前瞻性陈述,这些前瞻性陈述是基于公司在本新闻稿发布之日所掌握的信息。这些前瞻性陈述是基于当前的估计和假设,会受到各种风险和不确定性的影响,包括但不限于公司提交给美国证券交易委员会的报告中陈述的风险和不确定性。因此,实际结果可能会有很大不同。除法律要求外,本公司不承担在本新闻稿发布之日后因新信息、未来事件或其他原因而更新这些陈述的义务。此类前瞻性陈述会受到风险(包括公司在提交给美国证券交易委员会的经修订的截至2021年12月31日的财政年度10-K表格中陈述的风险)和不确定性因素的影响,这些风险和不确定性可能会导致实际结果与前瞻性陈述不同。
Pasithea Therapeutics Corp. Company Contact
Pasithea治疗公司联系人
Dr. Tiago Reis Marques
Chief Executive Officer
E: tiago@pasithea.com
蒂亚戈·里斯·马奎斯博士
首席执行官
电子邮件:tiago@pasithea.com
Pasithea Therapeutics Corp. Investor Relations
Pasithea治疗公司投资者关系
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
丽莎·M·威尔逊
现场通信公司
T: 212-452-2793
电子邮箱:lwilson@insiteconi.com
Pasithea Therapeutics Corp. Media Contact
Pasithea治疗公司媒体联系方式
Caitlin Kasunich
KCSA
E: ckasunich@kcsa.com
凯特琳·卡苏尼奇
KCSA
电子邮箱:ckasunich@kcsa.com
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧